Evidence map›Paper›PMID 32721879›Full record

ArticleMolecular therapy. Nucleic acids2020

Whole-Transcriptome Sequencing Identifies Key Differentially Expressed mRNAs, miRNAs, lncRNAs, and circRNAs Associated with CHOL.

Kai-Jian Chu, Yu-Shui Ma, Xiao-Hui Jiang, Ting-Miao Wu, Zhi-Jun Wu, Zhi-Zhen Li, Jing-Han Wang, Qing-Xiang Gao, Bin Yi, Yi Shi and 7 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04871321 (Discovery of Molecular Biomarkers for Predicting Response Through RNA Sequencing in Patients With Advanced Biliary Tract Cancer Who Received Nab-paclitaxel Plus Gemcitabine-cisplatin), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04871321 completednot on this mapstarted 2021, after this paper: background citation

Discovery of Molecular Biomarkers for Predicting Response Through RNA Sequencing in Patients With Advanced Biliary Tract Cancer Who Received Nab-paclitaxel Plus Gemcitabine-cisplatin

Typeobservational_patient_registrySponsorCHA UniversityRan2021 to 2023Enrolled119ConditionsBiliary Tract Cancer, Cholangiocarcinoma, Gallbladder CancerArmsnab-paclitaxel plus gemcitabine-cisplatin
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Kai-Jian ChuDepartment of Biliary Tract Surgery I, Third Affiliated Hospital of Second Military Medical University, Shanghai 200438, China.
Yu-Shui MaCancer Institute, Nantong Tumor Hospital, Nantong 226631, China; Department of Radiology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei 230012, China; Central Laboratory for Medical Research, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Xiao-Hui JiangGeneral Surgery, Nantong Tumor Hospital, Nantong 226631, China.
Ting-Miao WuDepartment of Radiology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei 230012, China.
Zhi-Jun WuDepartment of Oncology, Nantong Second People's Hospital, Nantong 226002, China.
Zhi-Zhen LiDepartment of Biliary Tract Surgery I, Third Affiliated Hospital of Second Military Medical University, Shanghai 200438, China.
Jing-Han WangDepartment of Biliary Tract Surgery I, Third Affiliated Hospital of Second Military Medical University, Shanghai 200438, China.
Qing-Xiang GaoDepartment of Biliary Tract Surgery I, Third Affiliated Hospital of Second Military Medical University, Shanghai 200438, China.
Bin YiDepartment of Biliary Tract Surgery I, Third Affiliated Hospital of Second Military Medical University, Shanghai 200438, China.
Yi ShiCancer Institute, Nantong Tumor Hospital, Nantong 226631, China.
Hui-Min WangCancer Institute, Nantong Tumor Hospital, Nantong 226631, China.
Li-Peng GuCentral Laboratory for Medical Research, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
Su-Qing ZhangDepartment of Hepatobiliary Surgery, Nantong Tumor Hospital, Nantong 226631, China.
Gao-Ren WangCancer Institute, Nantong Tumor Hospital, Nantong 226631, China.
Ji-Bin LiuCancer Institute, Nantong Tumor Hospital, Nantong 226631, China. Electronic address: tians2008@163.com.
Da FuDepartment of Radiology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei 230012, China; Central Laboratory for Medical Research, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China. Electronic address: fu800da900@126.com.
Xiao-Qing JiangDepartment of Biliary Tract Surgery I, Third Affiliated Hospital of Second Military Medical University, Shanghai 200438, China. Electronic address: jxq1225@sina.com.
Nantong Tumor Hospital · CNSecond Military Medical University · CNFourth Affiliated Hospital of Anhui Medical University · CNSecond People's Hospital of NanTong · CNShanghai Tenth People's Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To systematically evaluate the whole-transcriptome sequencing data of cholangiocarcinoma (CHOL) to gain more insights into the transcriptomic landscape and molecular mechanism of this cancer, we performed whole-transcriptome sequencing based on the tumorous (C) and their corresponding non-tumorous adjacent to the tumors (CP) from eight CHOL patients. Subsequently, differential expression analysis was performed on the C and CP groups, followed by functional interaction prediction analysis to investigate gene-regulatory circuits in CHOL. In addition, The Cancer Genome Atlas (TCGA) for CHOL data was used to validate the results. In total, 2,895 differentially expressed messenger RNAs (dif-mRNAs), 56 differentially expressed microRNAs (dif-miRNAs), 151 differentially expressed long non-coding RNAs (dif-lncRNAs), and 110 differentially expressed circular RNAs (dif-circRNAs) were found in CHOL samples compared with controls. Enrichment analysis on those differentially expressed genes (DEGs) related to miRNA, lncRNA, and circRNA also identified the function of spliceosome. The downregulated hsa-miR-144-3p were significantly enriched in the competing endogenous RNA (ceRNA) complex network, which also included 7 upregulated and 13 downregulated circRNAs, 7 upregulated lncRNAs, and 90 upregulated and 40 downregulated mRNAs. Moreover, most of the DEGs and a few of the miRNAs (such as hsa-miR-144-3p) were successfully validated by TCGA data. The genes involved in RNA splicing and protein degradation processes and miR-144-3p may play fundamental roles in the pathogenesis of CHOL.

Indexed as

ceRNACHOLDEGmiR-144-3pspliceosome

Identifiers

PMID32721879
PMCPMC7390861
OpenAlexW3037807121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.